08/03/2005
ReGen Therapeutics Plc (the ‘Company’) today announces that it has appointed Dr Peter Garrod to be a non-executive director of the Company with immediate effect.
Peter Garrod commented ‘I was introduced to a natural product for the potential treatment of Alzheimer’s disease in 1998. I have followed and supported ReGen with absolute dedication in their quest for a treatment for this debilitating condition.
I have always been at the forefront of advances in technology in my own field and feel that my input will enhance the progress and development of ReGen and will endeavour to support the best interests of the shareholders’.
Percy Lomax the Chairman and Chief Executive of the Company commented ‘I welcome Peter Garrod to the Board. As a major shareholder his backing for the Board is important, but I believe that his scientific and business experience, together with his enthusiasm to produce a better treatment for Alzheimer’s disease will be major assets to ReGen’.
Dr Garrod was born on 24th October 1950 and was educated at the London Hospital, part of the University of London. He graduated with a BDS and is a LDS of the Royal College of Surgeons. He has been the Senior Partner of the Bower Dental Centre, which specialises in advanced dental cosmetic surgery, for the last 18 years. There are no details to be disclosed pursuant to paragraphs (f)(iii) to (viii) of Schedule 2 to the AIM Rules.
Dr Garrod currently holds and is beneficially interested in 36,000,000 ordinary shares of the Company representing 10.5% of the current issued share capital of the Company.
For further information, please contact:
Andrew Marshall
Marshall Robinson Roe
Tel No 020 7960 6007